Resistant and relapsing neuroblastoma: improved response rate with a new multiagent regimen (OC-HDP) including high-dose cisplatinum.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Medical and Pediatric Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/MPO.2950150105PMID 3561328
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26.

  1984cited by this paper
• Dose‐response and dose‐survival advantage for high versus low‐dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group study

  1984cited by this paper
• Use of panels of monoclonal antibodies in the differential diagnosis of neuroblastoma and lymphoblastic disorders.

  1983cited by this paper
• Treatment of poor prognosis nonseminomatous testicular cancer with a “high‐dose” platinum combination chemotherapy regimen

  1983cited by this paper
• High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.

  1982cited by this paper
• Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report.

  1981cited by this paper
• Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration.

  1981cited by this paper
• Clinical evaluation of sequentially scheduled cisplatin and vm26 in neuroblastoma: Response and toxicity

  1981cited by this paper
• Neuroblastoma: review of the literature and an examination of factors contributing to its enigmatic charcter.

  1976cited by this paper

• Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.

  2009cites this paper
• Platinum Compound-Related Ototoxicity in Children: Long-Term Follow-Up Reveals Continuous Worsening of Hearing Loss

  2004cites this paper
• Positive direct antiglobulin test in a pediatric patient following high-dose cisplatin

  2004cites this paper
• Morphological change and cellular differentiation induced by cisplatin in human neuroblastoma cell lines

  2004cites this paper
• Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.

  2003cites this paper
• Integrated care in Europe: description and comparison of integrated care in six EU countries

  2003cites this paper
• Ototoxic Impact of Cisplatin in Pediatric Oncology Patients

  1999cites this paper
• Long‐term Survival in Refractory Recurrent Neuroblastoma

  1996cites this paper
• Synthesis and biological activity of five-coordinate platinum(II) complexes including organotin fragments.

  1995cites this paper
• Morphometric analysis of cisplatin-induced neurite outgrowth in N1E-115 neuroblastoma cells.

  1994cites this paper
• Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for Neuroblastoma.

  1993cites this paper
• Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation.

  1993cites this paper
• Standard-dose and high-dose peptichemio and cisplatin in children with disseminated poor-risk neuroblastoma: two studies by the Italian Cooperative Group for Neuroblastoma.

  1992cites this paper
• Unpurged autologous bone marrow transplantation for neuroblastoma: the AIEOP-BMT group experience.

  1991cites this paper
• Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases.

  1991cites this paper
• Coordinate change of c-myc, transferrin receptor and H3 gene expression precedes induction of haemoglobin-producing cells of the leukaemia K562 cell line treated with cis-diamminedichloroplatinum (II).

  1991cites this paper
• Did BMT change the clinical course of neuroblastoma?

  1991cites this paper
• Cis‐platinum ototoxicity in children

  1991cites this paper
• Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma.

  1991cites this paper
• Expression of multiple drug resistance gene, MDR1, and N-myc oncogene in an Italian population of human neuroblastoma patients.

  1990cites this paper
• Ototoxicity of preradiation cisplatin for children with central nervous system tumors.

  1990cites this paper
• Ototoxicity of cisplatinum in children and adolescents.

  1990cites this paper
• The role of chemotherapy in the treatment of children with neuroblastoma stage IV: The GPO (German Pediatric Oncology Society) experience

  1990cites this paper
• Cisplatin neurotoxicity.

  1989cites this paper
• Cytogenetic and molecular study of two human neuroblastoma cell lines.

  1988cites this paper
• Ototoxicity of high-dose cis-platinum in children.

  1988cites this paper